These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28910514)
1. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. Le J; Bradley JS; Hingtgen S; Skochko S; Black N; Jones RN; Lim M; Capparelli EV Pediatr Pulmonol; 2017 Nov; 52(11):1424-1434. PubMed ID: 28910514 [TBL] [Abstract][Full Text] [Related]
2. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559 [TBL] [Abstract][Full Text] [Related]
4. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion. Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. Drusano GL J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453 [TBL] [Abstract][Full Text] [Related]
8. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections. Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. Li J; Das S; Zhou D; Al-Huniti N Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546 [TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060 [TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Canut A; Isla A; Rodríguez-Gascón A Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566 [TBL] [Abstract][Full Text] [Related]
14. Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. Cannavino CR; Mendes RE; Sader HS; Farrell DJ; Critchley IA; Biek D; Le J; Skochko SM; Jones RN; Bradley JS Pediatr Infect Dis J; 2016 Jul; 35(7):813-5. PubMed ID: 27093165 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680 [TBL] [Abstract][Full Text] [Related]